New Alzheimer's Disease Target and a Potentially Broad Drug Discovery Approach
This article was originally published in Start Up
Researchers have identified a new target in Alzheimer's disease--the natural substrate of an enzyme that itself has long been a target for AD drug development. That the molecule appears to be druggable is itself a surprising observation that may offer valuable insight into how to improve AD drugs. More than that, however, it suggests that substrates of protease inhibitors may provide a completely new set of drug targets in a variety of diseases.
You may also be interested in...
Use of a library of synthetic peptide-like molecules as a screen to identify disease-specific antibodies in serum has led to identification of biomarkers for Alzheimer's disease that could form the basis of a blood-based diagnostic test. The screening strategy may also be broadly applicable to the development of diagnostics for other diseases, for identifying antibody targets in autoimmune diseases, and even as the basis for vaccine development.
Inhibitors of histone deacetylases have been developed as cancer drugs, with only limited use because of toxicities. Now, a research team has shown that HDAC2 impairs memory and learning, suggesting that inhibitors targeting only that molecule could be used to treat neurodegenerative diseases. Buoyed by these new observations, companies with HDAC inhibitors in hand can screen their libraries specifically for activity against this newly-understood target.
Each week, "The Pink Sheet" presents commentary on some of the week's most interesting business deals, contributed by the editors of the In Vivo blog. Visit the blog at 1http://invivoblog.blogspot.com/.